AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 8129129
Drug: Conventional technique
RxNorm normalized name: zinc pyrithione
DrugBank: Pyrithione (DB06815)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional technique with Bain system and tightly-fitting anaesthetic face-mask at 8 l.min-1
Trial: 8129129
Drug: Hudson mask
RxNorm normalized name: MASK,TRACHEOSTOMY HUDSON #1075
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hudson mask with Bain system at 8 l.min-1
Trial: 2657954
Drug: General practice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: General practice antenatal care (not specified dosage or duration)
Trial: 2657954
Drug: Medication prescribed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication prescribed during pregnancy
Trial: 5307603
Drug: Heat-killed broth-grown
RxNorm normalized name: brown mixture
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heat-killed broth-grown sorbed dried vaccine (vaccine G-66)
Trial: 5307603
Drug: Other types
RxNorm normalized name: collagen type I
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Other types of typhoid vaccines
Trial: 5307603
Drug: Heat-killed broth-grown
RxNorm normalized name: brown mixture
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heat-killed broth-grown and acetone-killed agar-grown vaccines
Trial: 26256065
Drug: Amlodipine, 5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amlodipine, 5 mg daily; Citalopram, 20 mg daily
Trial: 26256065
Drug: Amlodipine, 5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amlodipine, 5 mg daily
Trial: 15073471
Drug: Eplerenone 50
RxNorm normalized name: eplerenone 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eplerenone 50 mg once daily for 8 weeks
Trial: 15073471
Drug: Eplerenone 100
RxNorm normalized name: eplerenone 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eplerenone 100 mg once daily for 8 weeks
Trial: 15073471
Drug: Eplerenone 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eplerenone 200 mg once daily for 8 weeks
Trial: 11932279
Drug: DHEA supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DHEA supplementation (90 mg orally/d)
Trial: 7640316
Drug: Small-volume hypocaloric
RxNorm normalized name: Hydrochloric Acid
DrugBank: Hydrochloric acid (DB13366)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Small-volume hypocaloric continuous feedings (1 ml/kg/h), beginning at 24 h of age
Trial: 7640316
Drug: NPO group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NPO group (standard intravenous fluid and nutrition, nothing per OS)
Trial: 2680286
Drug: co-dergocrine mesylate
RxNorm normalized name: co-dergocrine mesylate
DrugBank: Ergoloid mesylate (DB01049)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: co-dergocrine mesylate (3 mg daily intravenous infusion over 14 days)
Trial: 187313
Drug: Simultaneous treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simultaneous treatment with methotrexate, cyclophosphamide, procarbazine, and vincristine
Trial: 187313
Drug: Sequential treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential treatment with methotrexate, cyclophosphamide, procarbazine, and vincristine
Trial: 187313
Drug: Simultaneous treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simultaneous treatment in patients with anaplastic small cell carcinoma
Trial: 187313
Drug: Sequential treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential treatment in patients with anaplastic small cell carcinoma
Trial: 187313
Drug: Simultaneous treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simultaneous treatment in patients with epidermoid carcinoma
Trial: 187313
Drug: Sequential treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential treatment in patients with epidermoid carcinoma
Trial: 187313
Drug: Maintenance therapy
RxNorm normalized name: Dental Resources Perio Maintenance Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maintenance therapy with continued four-drug polychemotherapy
Trial: 30710211
Drug: Enteral administration
RxNorm normalized name: IV solutions used in parenteral administration of fluids, electrolytes and nutrients
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enteral administration of 4.5 g of arginine and 10 g of glutamine per day for 7 days prior to surgery
Trial: 19086236
Drug: Alvimopan (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alvimopan (both doses) in PCA group (n = 317)
Trial: 19086236
Drug: Alvimopan (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alvimopan (both doses) in non-PCA group (n = 318)
Trial: 7853733
Drug: Acetylcholine infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetylcholine infusion (15 eyes)
Trial: 7853733
Drug: Balanced salt
RxNorm normalized name: Balanced Salt Solution
DrugBank: Magnesium chloride (DB09407)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Balanced salt solution (BSS) infusion (control, 22 eyes)
Trial: 3925488
Drug: 0.3 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.3 mg/kg methylphenidate
Trial: 3925488
Drug: 1.0 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.0 mg/kg methylphenidate
Trial: 3098
Drug: Cardioselective beta-blockers
RxNorm normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cardioselective beta-blockers (practolol, H 87/07, metoprolol)
Trial: 26140943
Drug: Reconstituted HDL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reconstituted HDL (rHDL) 40 mg/kg
Trial: 23268367
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg tabalumab
Trial: 23268367
Drug: 80 mg
RxNorm normalized name: RNA 180 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 80 mg tabalumab
Trial: 29374382
Drug: 30 mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg/day zinc supplementation
Trial: 19283648
Drug: Psychiatric treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psychiatric treatment as usual (TAU) without group sessions
Trial: 17229079
Drug: Daclizumab, mycophenolate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daclizumab, mycophenolate mofetil (MMF), corticosteroids (CS) and low‐dose CsA (target trough levels of 50‐100 ng/mL), weaned from month 4 and withdrawn by month 6
Trial: 17229079
Drug: Daclizumab, MMF,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daclizumab, MMF, CS and low‐dose CsA
Trial: 17229079
Drug: Low‐dose CsA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low‐dose CsA group
Trial: 17229079
Drug: Standard‐dose CsA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard‐dose CsA group
Trial: 15820814
Drug: Leuprolide acetate
RxNorm normalized name: Leuprolide Acetate
DrugBank: Leuprolide (DB00007)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Leuprolide acetate depot (LAD, 11.25 mg IM/3 months) plus tibolone (group A)
Trial: 15820814
Drug: Leuprolide acetate
RxNorm normalized name: Leuprolide Acetate
DrugBank: Leuprolide (DB00007)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Leuprolide acetate depot (LAD, 11.25 mg IM/3 months) plus placebo tablets (group B)
Trial: 15820814
Drug: Injection of
RxNorm normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection of a placebo solution plus placebo tablets (group C)
Trial: 12212781
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg of mifepristone daily for 6 months
Trial: 8564348
Drug: Disodium pamidronate
RxNorm normalized name: Disodium pamidronate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Disodium pamidronate 60 mg
Trial: 31277138
Drug: Celecoxib combined
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Celecoxib combined with chemotherapy
Trial: 31277138
Drug: Celecoxib combined
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Celecoxib combined with chemotherapy (for COX-2 positive patients)
Trial: 29276907
Drug: Sotalol (162.5±46.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sotalol (162.5±46.2 mg/day, n=24)
Trial: 25115995
Drug: 5% Sodium
RxNorm normalized name: Dextrose 5% and 0.45% Sodium Chloride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5% Sodium hypochlorite (NaOCl) used as a cleansing agent in pulpotomy procedures
Trial: 1882896
Drug: Sucralfate 1
RxNorm normalized name: sucralfate 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sucralfate 1 g granulate four times daily
Trial: 6309542
Drug: Enprofylline (3.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enprofylline (3.5 mg/kg)
Trial: 6309542
Drug: Theophylline (9.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Theophylline (9.5 mg/kg)
Trial: 30634195
Drug: Low-volume bowel
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-volume bowel preparation (0.3L sodium picosulfate with magnesium citrate)
Trial: 8956371
Drug: Luteal phase
RxNorm normalized name: Nuphar lutea leaf extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Luteal phase (L)
Trial: 15750042
Drug: Bosentan (62.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bosentan (62.5 mg twice daily for 4 weeks, then 125 mg twice daily)
Trial: 8686962
Drug: Both dosage
RxNorm normalized name: osage orange pollen extract
DrugBank: Maclura pomifera pollen (DB10988)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both dosage regimens
Trial: 21422768
Drug: Eicosapentaenoic acid
RxNorm normalized name: eicosapentaenoic acid
DrugBank: Icosapent (DB00159)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Eicosapentaenoic acid (E-EPA) 1 g/day
Trial: 16897990
Drug: S-1 (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S-1 (80 mg/m2/day for 4 weeks followed by 2 weeks rest for a year)
Trial: 16897990
Drug: UFT (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UFT (400 mg/m2/day for 5 days followed by 2 days rest for a year)
Trial: 15163474
Drug: Mg +
RxNorm normalized name: Citracal 250 mg + D
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mg + Zn (200 mg Mg and 30 mg Zn)
Trial: 9159306
Drug: Calcium channel
RxNorm normalized name: Calcium channel blocker
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium channel blocker regimen (amlodipine)
Trial: 9159306
Drug: Beta-blocker regimen
RxNorm normalized name: Anacin Aspirin Regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta-blocker regimen (atenolol)
Trial: 27702823
Drug: Cabazitaxel 25
RxNorm normalized name: Cabazitaxel
DrugBank: Cabazitaxel (DB06772)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cabazitaxel 25 mg/m2 every 3 weeks plus prednisone 10 mg/day (group CABA)
Trial: 27702823
Drug: Cabazitaxel 25
RxNorm normalized name: Cabazitaxel
DrugBank: Cabazitaxel (DB06772)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cabazitaxel 25 mg/m2 every 3 weeks with concomitant budesonide 9 mg daily during the first two treatment cycles (group BUD)
Trial: 16306998
Drug: Telmisartan 80
RxNorm normalized name: telmisartan 80 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telmisartan 80 mg/HCTZ 12.5 mg o.d.
Trial: 25226328
Drug: Massage treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Massage treatment for 15 minutes by physiotherapist, consisting of light stroking, milking, friction, and skin rolling.
Trial: 19926058
Drug: High-dose sirolimus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose sirolimus
Trial: 2478778
Drug: Transdermally delivered
RxNorm normalized name: DELIVER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermally delivered nitroglycerin (NTG 10 mg/24 h)
Trial: 17171330
Drug: Collagen implant
RxNorm normalized name: Collagen implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Collagen implant (CMI) with high tibial valgus osteotomy
Trial: 14501397
Drug: Moist Exposed
RxNorm normalized name: lactose, x-ray exposed (1000 rad)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moist Exposed Burn Ointment (MEBO)
Trial: 3890394
Drug: muzolimine (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: muzolimine (20 mg o.d.)
Trial: 3890394
Drug: acebutolol (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: acebutolol (400 mg o.d.)
Trial: 29197947
Drug: Adapted dialectical
RxNorm normalized name: ADAPT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adapted dialectical behavior therapy (DBT) skills training for 10 sessions
Trial: 30439812
Drug: D +
RxNorm normalized name: Liver Desiccated + B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: D + ASA (Duloxetine + Acetylsalicylic Acid 100 mg)
Trial: 27029487
Drug: Deferiprone (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Deferiprone (20 mg/kg/day)
Trial: 24908096
Drug: Standard speech
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard speech and language therapy (dose determined by individual needs, not exceeding eight weeks of treatment)
Trial: 24908096
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (standard care with no speech and language therapy input for at least six months post-randomization)
Trial: 10857839
Drug: Timolol with
RxNorm normalized name: timolol
DrugBank: Timolol (DB00373)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Timolol with systemic beta-blockers
Trial: 10857839
Drug: Brimonidine with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brimonidine with systemic beta-blockers
Trial: 10857839
Drug: Brimonidine without
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brimonidine without systemic beta-blockers
Trial: 24854306
Drug: ACTH stimulation
RxNorm normalized name: ACTH
DrugBank: Corticotropin (DB01285)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ACTH stimulation test with 250 μg of synthetic ACTH administered intravenously on Days 1, 2, 3, 5, and 7 after traumatic injury
Trial: 24854306
Drug: CIRCI patients
RxNorm normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CIRCI patients with Δcortisol < 9 μg/dL
Trial: 24854306
Drug: Δcortisol <
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Δcortisol < 9 μg/dL
Trial: 2163701
Drug: Antibiotic-impregnated fine-mesh
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Antibiotic-impregnated fine-mesh greased gauze covering remaining areas of the wounds
Trial: 326347
Drug: Vole bacillus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vole bacillus vaccine
Trial: 31277561
Drug: Canakinumab (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Canakinumab (150 mg subcutaneously)
Trial: 25614164
Drug: Riociguat, individually
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Riociguat, individually adjusted up to a maximum dose of 2.5 mg three times daily
Trial: 23519546
Drug: nebivolol 5-40
RxNorm normalized name: nebivolol 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: nebivolol 5-40 mg/day
Trial: 19172849
Drug: Statin or
RxNorm normalized name: nystatin Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Statin or immunosuppressive therapy
Trial: 16878035
Drug: rHuEPO 40,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rHuEPO 40,000 units administered weekly for up to 12 doses
Trial: 8087328
Drug: ICI 204,219
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ICI 204,219 40 mg
Trial: 7767514
Drug: ICI 204,219
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ICI 204,219 100 mg
Trial: 6500225
Drug: Nifedipine 10
RxNorm normalized name: nifedipine 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nifedipine 10 mg four times a day
Trial: 30665602
Drug: Simultaneous tobacco
RxNorm normalized name: Tobacco leaf
DrugBank: Tobacco leaf (DB10710)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simultaneous tobacco intervention (TI) combining web-based counseling with nicotine replacement therapy (NRT) during weeks 1-12.
Trial: 30665602
Drug: Sequential tobacco
RxNorm normalized name: Tobacco leaf
DrugBank: Tobacco leaf (DB10710)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential tobacco intervention (TI) delayed until weeks 13-24.
Trial: 25684233
Drug: Vanoxerine 400
RxNorm normalized name: Vanoxerine
DrugBank: Vanoxerine (DB03701)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vanoxerine 400 mg
Trial: 22160549
Drug: Lidocaine pretreatment
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lidocaine pretreatment (1% lidocaine 2 ml)
Trial: 11853711
Drug: 0.12% isopropyl
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.12% isopropyl unoprostone (Rescula) applied twice a day for 21 days
Trial: 11853711
Drug: Placebo applied
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo applied twice a day for 21 days
Trial: 9798136
Drug: 0.625‐mg conjugated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.625‐mg conjugated equine estrogen plus 5‐mg medroxyprogesterone acetate (MPA)
Trial: 9798136
Drug: 0.625‐mg conjugated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.625‐mg conjugated equine estrogen plus 2.5‐mg MPA
Trial: 7825160
Drug: 6 mg
RxNorm normalized name: boron 6 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 mg of warfarin per day for 3 days (Group I)
Trial: 7825160
Drug: 8 mg
RxNorm normalized name: alloin 8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8 mg of warfarin twice a day for 2 or 3 days (Group II)
Trial: 3364147
Drug: 10 mg.kg‐1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg.kg‐1 of 1.5% lidocaine
Trial: 24302687
Drug: Early iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Early iron (EI) supplementation (2 mg/kg/day elemental iron)
Trial: 22273632
Drug: IL‐1 receptor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IL‐1 receptor antagonist (IL‐1Ra) 150 mg
Trial: 14739212
Drug: Low-dose aspirin
RxNorm normalized name: low-dose aspirin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-dose aspirin 100 mg daily
Trial: 14739212
Drug: Low-molecular-weight heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-molecular-weight heparin enoxaparin 40 mg
Trial: 10690604
Drug: Octreotide infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Octreotide infusion (50 micrograms/h for 12 hours following initial 50 micrograms i.v. bolus)
Trial: 9369912
Drug: Cisplatin‐based chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisplatin‐based chemotherapy regimen
Trial: 8335204
Drug: Heme arginate
RxNorm normalized name: Heme arginate
DrugBank: Heme arginate (DB17310)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heme arginate (3 mg/kg)
Trial: 8335204
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of heme arginate (3 mg/kg) and tin protoporphyrin (1 mumol/kg)
Trial: 2544688
Drug: Intermittent metoclopramide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent metoclopramide (regimen A): lorazepam 1 mg orally, dexamethasone 10 mg IV every four hours for three doses, diphenhydramine 0.5 mg/kg IV every four hours for three doses, metoclopramide 1 mg/kg IV bolus every two hours for six doses
Trial: 2544688
Drug: Continuous infusion
RxNorm normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous infusion metoclopramide (regimen B): identical to regimen A except metoclopramide was administered as 1 mg/kg IV bolus followed by 0.5 mg/kg/h for ten hours
Trial: 23849614
Drug: Biscem cement
RxNorm normalized name: Cement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biscem cement (Sub-group A, L, C)
Trial: 23849614
Drug: Maxcem Elite
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maxcem Elite (Sub-group A, L, C)
Trial: 19833860
Drug: Telbivudine 600
RxNorm normalized name: telbivudine 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telbivudine 600 mg/d for 7 days
Trial: 19833860
Drug: Telbivudine 1800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telbivudine 1800 mg/d for 7 days
Trial: 19833860
Drug: Moxifloxacin 400
RxNorm normalized name: moxifloxacin 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moxifloxacin 400 mg (positive calibrator)
Trial: 16721396
Drug: Natural mixed
RxNorm normalized name: Xymogen Optimag Neuro Natural Mixed Berry
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Natural mixed carotenoids supplementation (120,000 IU of beta-carotene daily)
Trial: 20099987
Drug: Ziprasidone 40
RxNorm normalized name: ziprasidone 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ziprasidone 40 mg/day
Trial: 10192829
Drug: Ziprasidone 80
RxNorm normalized name: ziprasidone 80 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ziprasidone 80 mg/day
Trial: 11199944
Drug: Ziprasidone 120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ziprasidone 120 mg/day
Trial: 20099987
Drug: Ziprasidone 160
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ziprasidone 160 mg/day
Trial: 12177583
Drug: Ziprasidone (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ziprasidone (all doses)
Trial: 8355037
Drug: 1 year
RxNorm normalized name: COVID vacc 2024-2025 (5-11 years) (Pfizer)/PF 10 mcg/0.3 mL INTRAMUSC VIAL (ML)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 year of adjuvant CMFVP chemotherapy
Trial: 8355037
Drug: 2 years
RxNorm normalized name: Childrens Panadol 5 - 12 Years
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 years of adjuvant CMFVP chemotherapy
Trial: 16226759
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg sublingual nitroglycerin